TPC Group Inc. (Nasdaq:TPCG) reported that its the Board of Directors has approved its strategic project to produce on-purpose isobutylene. The project includes refurbishment and restart of certain of its dehydrogenation assets at the Companys Houston Operations.
These dehydrogenation assets will serve to provide isobutylene feedstock for the Companys performance products and fuels business, including MTBE, polyisobutylene, high purity isobutylene and diisobutylene.
Crown Equity Holdings Inc., (CRWE) offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them.
CRWEs advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness.
CRWEs division CRWE AD-Services (www.crwe-adservices.com), is a full service multimedia advertising company specializing in internet marketing. It provides modern and unique advertising campaigns, dedicated to offering the most cost effective advertising solutions.
More about CRWE at www.crownequityholdings.com.
Tranzyme Pharma (Nasdaq:TZYM), reported that it has agreed to sell approximately 2.6 million shares of its common stock at a price of $3.85 per share in a registered direct offering.
The offering will raise gross proceeds to Tranzyme of approximately $10.0 million before deducting underwriters discounts and other offering expenses. Tranzyme has also granted the underwriters a 30-day option to purchase up to an additional fifteen percent of the shares of common stock offered to cover over-allotments, if any, which would result in additional gross proceeds of approximately $1.5 million if exercised in full.
DUSA Pharmaceuticals, Inc.(r) (Nasdaq:DUSA), a dermatology company that is developing and marketing its Levulan(r) (aminolevulinic acid HCl) Photodynamic Therapy (PDT) platform, reported results of an investigational study designed to examine and compare the safety and efficacy of broad area application of the Levulan(r) Kerastick(r) with or without occlusive dressing (where the treatment area is covered or wrapped) in conjunction with the BLU-U(r) for the treatment of minimally to moderately thick actinic keratoses (AKs) on the upper extremities. The study showed a statistically significant lesion reduction and complete clearance of actinic keratoses of the extremities (hands and arms) when compared to treatment with vehicle.
The use of occlusion resulted in a statistically significant improvement in lesion clearance rates compared to treatment without occlusion. The study utilized the Levulan(r) Kerastick(r) (aminolevulinic acid HCl) for Topical Solution, 20% with the BLU-U(r) Blue Light Photodynamic Therapy Illuminator which is FDA approved for the treatment of minimally to moderately thick actinic keratoses (AKs) of the face or scalp.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: CRWENewswire.co.uk publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. (Read Full Disclaimer at http://CRWENewswire.co.uk/disclaimer)